Stay updated with breaking news from Mission bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mission Bio Inc. released its Tapestri single-cell minimal residual disease (MRD) assay for acute myeloid leukemia (AML) on September 26, with the goal of enabling greater personalization of care for patients with blood cancers. The test can provide insights into the progression of AML and help identify targets for treatment in addition to identifying patients truly experiencing relapse as distinct from having pre-leukemic or precursor clones.
Mission Bio Announces Launch of Single-Cell Measurable Residual Disease (MRD) Assay Aimed to Advance Personalized Healthcare for Blood Cancer Patients kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.
Improved detection of measurable residual disease in acute myeloid leukemia science.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from science.org Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ -- The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and...
Dublin, July 21, 2023 (GLOBE NEWSWIRE) -- The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and...
DUBLIN--(BUSINESS WIRE)--The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.The global MRD testing market is projected to reach $6.67 billion by 2033...